Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27056989 | 0.82 | POLB (0.44) | TSHRHRH3LMNA | |
| SCHEMBL27056976 | 0.81 | HRH3 (0.48) | TSHRKCNH2HRH3MEN1KMT2A | |
| SCHEMBL14578374 | 0.75 | CARM1 (0.60) | TSHRKCNH2HTR2ALMNA | |
| SCHEMBL27056970 | 0.75 | CARM1 (0.36) | HRH3MEN1KMT2A | |
| SCHEMBL123415 | 0.74 | MAPT (0.55) | TSHRMEN1KMT2AMAPTALOX12 | |
| SCHEMBL15114294 | 0.73 | LMNA (0.57) | TSHRMEN1KMT2AMAPTALOX12 | |
| SCHEMBL26501101 | 0.73 | ACACB (0.49) | MEN1KMT2AMAPTALOX12LMNA | |
| SCHEMBL13155583 | 0.71 | ACACB (0.53) | MEN1KMT2AMAPTALOX12LMNA | |
| SCHEMBL7477540 | 0.71 | NPC1 (0.54) | TSHRMEN1KMT2AMAPTALOX12 | |
| SCHEMBL4527180 | 0.71 | MAPT (0.50) | TSHRMEN1KMT2AMAPTALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | TSHR 2564/4885KCNH2 4877/4885HRH3 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.